The data showed that higher percentages of tumor-infiltrating CD8+ T cells were presented in both the CD5-CD30-MU-CAR-T group and the conventional CAR-T group, compared with those in control group or SdΔN17-28BBZ3 group (Fig. 6C). The gene discussed is CD5; the disease is neoplasm.